Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of
ALXN2050 in addition to background therapy consistent with the standard of care in adult
participants (≥ 18 to ≤ 75 years of age) with either LN or IgAN. The study will consist of an
up to 6-week Screening Period, a 26-week blinded Initial Evaluation Period, a 24-week blinded
Extended Treatment Period, and an Open-label Extension (OLE) Period of up to 2 years.
Safety will be monitored throughout the study.